SCHEMBL6399673

SCHEMBL6399673

CC(c1ccccc1)N(CC(O)CO)c1nc(O)nc(Nc2ccc3ncsc3c2)n1

nearest known ligand 0.45

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
KDR P35968 7/20 0.45
INSR P06213 4/20 0.45
TEK Q02763 4/20 0.45
PDGFRB P09619 3/20 0.45
PDGFRA P16234 3/20 0.45
CSF1R P07333 2/20 0.45
CFTR P13569 1/20 0.42
IRAK4 Q9NWZ3 7/20 0.41
MAP4K1 Q92918 1/20 0.41
SYK P43405 1/20 0.41
IKBKB O14920 4/20 0.40
JAK3 P52333 1/20 0.38
CHUK O15111 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6321943 0.89 CFTR (0.49) KDRINSRTEKPDGFRBPDGFRA
SCHEMBL6321949 0.89 CFTR (0.49) KDRINSRTEKPDGFRBPDGFRA
SCHEMBL6401617 0.89 CFTR (0.49) KDRINSRTEKPDGFRBPDGFRA
SCHEMBL6397207 0.84 KDR (0.51) KDRINSRTEKPDGFRBPDGFRA
SCHEMBL6313522 0.84 KDR (0.51) KDRINSRTEKPDGFRBPDGFRA
SCHEMBL6313512 0.84 KDR (0.51) KDRINSRTEKPDGFRBPDGFRA
SCHEMBL6315370 0.83 KDR (0.50) KDRINSRTEKPDGFRBPDGFRA
SCHEMBL28121258 0.81 KDR (0.48) KDRINSRTEKPDGFRBPDGFRA
SCHEMBL6393385 0.81 KDR (0.66) KDRINSRTEKPDGFRBPDGFRA
SCHEMBL6729957 0.77 IRAK4 (0.56) KDRINSRTEKPDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1549645-A1 4,6-DIAMINOSUBSTITUTED-2-[OXY OR AMINOXY]-[1,3,5]TRIAZINES AS PROTEIN TYROSINE KINASE INHIBITORS Johnson & Johnson Pharmaceutical Research & Development, Inc. (US) 2005-07-06 EP claimed
US-20040110758-A1 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2004-06-10 US claimed
WO-2004031184-A1 4,6-DIAMINOSUBSTITUTED-2-[OXY OR AMINOXY]-[1,3,5]TRIAZINES AS PROTEIN TYROSINE KINASE INHIBITORS JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, INC. (US) 2004-04-15 WO claimed
US-20050004092-A1 Penem derivatives and antimicrobial agent containing the same DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2005-01-06 US disclosed
US-20040110758-A1 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2004-06-10 US disclosed
EP-0757051-B1 PENEM DERIVATIVES AND ANTIMICROBIAL AGENT CONTAINING THE SAME DAIICHI SUNTORY PHARMA CO LTD (JP) 2003-10-29 EP disclosed
EP-0757051-A1 PENEM DERIVATIVES AND ANTIMICROBIAL AGENT CONTAINING THE SAME SUNTORY LIMITED (JP) 1997-02-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004092-A1 Penem derivatives and antimicrobial agent containing the same MRPL21, MRPS2, MRPS28 KDR 4534/4885INSR 2273/4885TEK 2379/4885
US-20040110758-A1 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors TIE1, KDR, FLT1 KDR 2/4885INSR 358/4885TEK 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.